IP-6 inhibits cancer cell growth
Inositol hexaphosphate (IP(6)) is a naturally occurring carbohydrate, abundantly present in many plant sources and in certain high-fiber diets, such as cereals and legumes. In addition to being found in plants, IP(6) is contained in almost all mammalian cells, although in much smaller amounts, where it is important in regulating vital cellular functions such as signal transduction, cell proliferation, and differentiation. For a long time IP(6) has been recognized as a natural antioxidant. Recently IP(6) has received much attention for its role in cancer prevention and control of experimental tumor growth, progression, and metastasis. In addition, IP(6) possesses other significant benefits for human health, such as the ability to enhance immune system, prevent pathological calcification and kidney stone formation, lower elevated serum cholesterol, and reduce pathological platelet activity. IP(6) is rapidly taken up into cells which further affect signal pathways resulting in cell cycle arrest. A striking anticancer action of IP(6) was demonstrated in different experimental models. In addition to reducing cell proliferation, IP(6) also induces differentiation of malignant cells. Enhanced immunity and antioxidant properties also contribute to tumor cell destruction. Preliminary studies in humans show that IP(6) and inositol, the precursor molecule of IP(6), appear to enhance the anticancer effect of conventional chemotherapy, control cancer metastases, and improve quality of life. Because it is abundantly present in regular diet, efficiently absorbed from the gastrointestinal tract, and safe, IP(6) + inositol holds great promise in our strategies for cancer prevention and therapy. Excerpt (Abstract: Protection against cancer by dietary IP6 and inositol. Nutr Cancer. 2006;55(2):109-25.)
About Dr. Abulkalam Shamsuddin M.B.B.S., Ph.D.
Dr Shamsuddin graduated Dhaka Medical College, University of Dhaka in 1972. Following Internship in Massachusetts and Residency training in pathology in Maryland, he was certified by the American Board of Pathology in 1977. In 1980, he received Ph.D. degree from the University of Maryland for his work on colon carcinogenesis. He joined the faculty of the University of Maryland as an Instructor in 1977, and rose through the ranks of Assistant Professor and Associate Professor to become a full Professor in 1988. For his excellence in teaching he received the Best Teacher award from the medical students many times, including the coveted “Golden Apple Award” by the American Medical Students’ Association in 1999.
Dr. Shamsuddin has been studying the process of cancer formation and the prevention of cancer since 1975. His research in the steps of colon cancer formation resulted in the development of a very simple and accurate screening test for colon cancer. This rather inexpensive test detects cancers at a very early stage, and even before they have formed; in other words, it can also detect precancerous polyps and other precancerous lesions and conditions. The test has been in use in China since the early 1990’s often referred to as “Shams’ Test.” He further discovered that the colon cancer marker Gal-GalNAc is a common cancer marker expressed through a similar “field-effect” phenomenon; thus forming the basis for a general cancer screening test such as for cancer of the lungs and breast, and possibly prostate and uterine cervix.
In mid 1985, Dr. Shamsuddin started his pioneering experiments on the anti-cancer property of inositol and inositol hexaphosphate (IP-6) – natural constituents of cereals and legumes such as rice, corn, beans etc. For the next two decades, he has reconfirmed and expanded his groundbreaking studies to show the efficacy of IP-6 and inositol against different cancers in various experimental models. Dr. Shamsuddin’s book on this “IP6: Nature’s Revolutionary Cancer Fighter” by Kensington Publishing Corporation, New York, 1998, is written for the general public. Aside from these Dr. Shamsuddin has contributed numerous book-chapters and published over 200 scientific papers.